JP2024511954A5 - - Google Patents
Info
- Publication number
- JP2024511954A5 JP2024511954A5 JP2023555737A JP2023555737A JP2024511954A5 JP 2024511954 A5 JP2024511954 A5 JP 2024511954A5 JP 2023555737 A JP2023555737 A JP 2023555737A JP 2023555737 A JP2023555737 A JP 2023555737A JP 2024511954 A5 JP2024511954 A5 JP 2024511954A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- seq
- oligonucleotide
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163160710P | 2021-03-12 | 2021-03-12 | |
| US63/160,710 | 2021-03-12 | ||
| PCT/US2022/020070 WO2022192754A2 (en) | 2021-03-12 | 2022-03-11 | Methods of treating myotonic dystrophy type 1 using peptide-oligonucleotide conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024511954A JP2024511954A (ja) | 2024-03-18 |
| JP2024511954A5 true JP2024511954A5 (https=) | 2025-04-03 |
Family
ID=83228538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023555737A Pending JP2024511954A (ja) | 2021-03-12 | 2022-03-11 | ペプチド－オリゴヌクレオチド複合体を用いる筋強直性ジストロフィー１型の治療法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240189434A1 (https=) |
| EP (1) | EP4304657A4 (https=) |
| JP (1) | JP2024511954A (https=) |
| CN (1) | CN117425499A (https=) |
| CA (1) | CA3212994A1 (https=) |
| WO (1) | WO2022192754A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200131231A1 (en) | 2017-02-17 | 2020-04-30 | Oxford University Innovation Limited | Cell penetrating peptides |
| GB201812980D0 (en) | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| GB201812972D0 (en) | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| US12465646B2 (en) | 2018-12-07 | 2025-11-11 | Oxford University Innovation Limited | Linkers |
| WO2024097310A2 (en) * | 2022-11-01 | 2024-05-10 | Impilo Therapeutics, Inc. | Targeted non-charged-nucleic acid (ncna) delivery and related tumor penetrating nanocomplexes |
| WO2025264554A1 (en) | 2024-06-17 | 2025-12-26 | Pepgen Inc. | Antisense oligonucleotide conjugates targeting peripheral myelin protein 22 (pmp22) and methods of use thereof |
| WO2026080471A2 (en) | 2024-10-07 | 2026-04-16 | Flagship Pioneering Innovations Vi, Llc | Compositions of trem conjugates and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9740817B1 (en) * | 2002-10-18 | 2017-08-22 | Dennis Sunga Fernandez | Apparatus for biological sensing and alerting of pharmaco-genomic mutation |
| EP2595663A4 (en) * | 2010-07-19 | 2014-03-05 | Isis Pharmaceuticals Inc | MODULATION OF DYSTROPHIA MYOTONICA PROTEIN KINASE (DMPK) EXPRESSION |
| EP3034074A1 (en) * | 2014-12-18 | 2016-06-22 | Universitat De València, Estudi General | Compound for treatment of myotonic dystrophy type 1 |
| US12465646B2 (en) * | 2018-12-07 | 2025-11-11 | Oxford University Innovation Limited | Linkers |
| GB201911403D0 (en) * | 2019-08-09 | 2019-09-25 | Univ Oxford Innovation Ltd | Conjugate and uses thereof |
| WO2022171972A1 (en) * | 2021-02-12 | 2022-08-18 | Oxford University Innovation Limited | Cell-penetrating peptide conjugates and methods of their use |
-
2022
- 2022-03-11 EP EP22768147.5A patent/EP4304657A4/en active Pending
- 2022-03-11 US US18/281,700 patent/US20240189434A1/en active Pending
- 2022-03-11 WO PCT/US2022/020070 patent/WO2022192754A2/en not_active Ceased
- 2022-03-11 CN CN202280034483.XA patent/CN117425499A/zh active Pending
- 2022-03-11 JP JP2023555737A patent/JP2024511954A/ja active Pending
- 2022-03-11 CA CA3212994A patent/CA3212994A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024511954A5 (https=) | ||
| JP2024511955A5 (https=) | ||
| JPWO2020209285A5 (https=) | ||
| Farrell | Polynuclear platinum drugs | |
| JP2024506099A5 (https=) | ||
| US11466274B2 (en) | Modified gapmer oligonucleotides and methods of use | |
| Zhou et al. | Modifications of aminoglycoside antibiotics targeting RNA | |
| JP7269968B2 (ja) | ペプチド担体上の多重オリゴヌクレオチド部分 | |
| AU2011367230A1 (en) | Peptide oligonucleotide conjugates | |
| WO2011150408A2 (en) | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | |
| JP2004537517A5 (https=) | ||
| CN106102730A (zh) | 作为抗微生物剂的聚阳离子两亲物 | |
| Aradi et al. | Aminoglycoside conjugation for RNA targeting: antimicrobials and beyond | |
| JP2020528910A5 (https=) | ||
| WO1995024222A1 (en) | Cyclic polycationic polymer-oligonucleotide conjugates and methods for preparing same | |
| WO2001076636A2 (en) | Pharmaceutical composition of modified pna molecules | |
| AU2021226089A1 (en) | Antisense nucleic acid inducing skipping of exon 51 | |
| WO2020201339A1 (en) | Oligonucleotides for modulating atxn2 expression | |
| JP2024532464A5 (https=) | ||
| US20190345495A1 (en) | Antisense oligonucleotides for modulating nfkb2 expression | |
| US20240336920A1 (en) | Threose nucleic acid antisense oligonucleotides and methods thereof | |
| JP2024525837A5 (https=) | ||
| US20190367920A1 (en) | Antisense oligonucleotides for modulating nfkb1 expression | |
| US11898145B2 (en) | Enhanced oligonucleotides for inhibiting RTEL1 expression | |
| Waring | Structural constraints in the binding of drugs to DNA |